16 December 2024 : Case report
[In Press] Dual Blood Purification with CytoSorb and oXiris in Managing Recurrent Septic Shock: A Case Report
Unusual clinical course, Unusual setting of medical care, Educational Purpose (only if useful for a systematic review or synthesis)
Bartłomiej Włochacz1ABCDEF, Andrzej Rybak1AB, Agnieszka Próchnicka1B, Bartosz Rustecki 1ABD, Daniel Wendt 2ABCDEF, Jakub Klimkiewicz 1ABCDEFDOI: 10.12659/AJCR.945952
Am J Case Rep In Press; DOI: 10.12659/AJCR.945952
Available online: 2024-12-16, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Extracorporeal blood purification strategies were recently developed as adjunctive treatments for sepsis. CytoSorb® is an approved medical device designed to reduce blood levels of inflammatory cytokines. The oXiris high-adsorption membrane filter is used in continuous hemofiltration adsorption. We describe the case of a 67-year-old man with recurrent septic shock, requiring treatment with antibiotics, vasopressors, inotropes, mechanical ventilation, continuous renal replacement therapy (CRRT), and adjunctive treatment with an oXiris filter and hemadsorption using the CytoSorb device.
CASE REPORT
A 67-year-old man was admitted to the Intensive Care Unit (ICU) with septic shock. He received antibiotics, fluids, vasopressors, and inotropes and was mechanically ventilated. Acute kidney failure was treated with CRRT. His condition improved, and he was transferred to the general ward. On day 3 in the ward, he developed a new episode of septic shock and was readmitted to ICU. Standard therapy with fluids, vasopressors, and empiric antibiotics was started. Despite treatment, his condition deteriorated dramatically. CRRT with an oXiris filter in combination with hemoadsorption using CytoSorb was started. After CRRT initiation and integration of the CytoSorb adsorber, rapid improvement in the patient’s condition was observed. Daily laboratory test results showed significant decreases in procalcitonin and CRP. The patient was discharged from ICU on day 5 after initiation of CytoSorb therapy.
CONCLUSIONS
Although no guidelines and large clinical trial data are yet available to support the use of CytoSorb and oXiris, this report supports the findings from previous reports and small studies, that they can be considered as adjunctive treatments for patients with sepsis.
Keywords: Critical Care; Endotoxins; Intensive Care Units; Sepsis; Shock, Septic
In Press
Case report
Post-Transplant Lymphoproliferative Disorder at the Porta Hepatis Causing Hepatic Artery Stenosis and Chole...Am J Case Rep In Press; DOI: 10.12659/AJCR.945837
Case report
Dual Blood Purification with CytoSorb and oXiris in Managing Recurrent Septic Shock: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.945952
Case report
Preserving Cervical Mobility: A Novel Robot-Assisted Approach for Atlas Fracture FixationAm J Case Rep In Press; DOI: 10.12659/AJCR.945718
Case report
Neonatal Familiar Cleidocranial Dysplasia: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.946322
Most Viewed Current Articles
21 Jun 2024 : Case report 82,334
Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report 48,898
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report 23,170
Azithromycin Treatment for Acne Vulgaris: A Case Report on the Risk of Clostridioides difficile InfectionDOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report 21,974
A Case of Thoracic Empyema Caused by Actinomyces naeslundiiDOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030